IMPACT OF A DATA-DRIVEN PREDICTION ALGORITHM FOR BLOOD VOLUME PROCESSING IN PERIPHERAL BLOOD STEM CELL COLLECTION IN UNRELATED (NMDP) HPC DONORS

Size: px
Start display at page:

Download "IMPACT OF A DATA-DRIVEN PREDICTION ALGORITHM FOR BLOOD VOLUME PROCESSING IN PERIPHERAL BLOOD STEM CELL COLLECTION IN UNRELATED (NMDP) HPC DONORS"

Transcription

1 IMPACT OF A DATA-DRIVEN PREDICTION ALGORITHM FOR BLOOD VOLUME PROCESSING IN PERIPHERAL BLOOD STEM CELL COLLECTION IN UNRELATED (NMDP) HPC DONORS Anand Padmanabhan, MD PhD QIA BloodCenter of Wisconsin Milwaukee, Wisconsin ASFA Annual Meeting 2017 Ft. Lauderdale, Florida

2 Disclosures Name Institution Disclosure Anand Padmanabhan, MBBS MA PhD BloodCenter of Wisconsin Terumo BCT, Mallinckrodt Pharmaceuticals, Schlesinger Associates, LEK Consulting, Angiodynamics, BCW 2

3 Background An important source of stem cells for hematopoietic stem cell transplantation (HSCT) is peripheral blood (PB) Hematopoietic stem cells (HPCs) are collected for HCSTs using large volume leukapheresis (LVL) that typically involves processing >4 blood volumes to ensure adequate collection of HPCs

4 Background Large volume leukapheresis of NMDP donors is time-intensive, causes volume overload, hypocalcemia and platelet depletion. We performed a quality improvement study to generate a collection efficiency-based, data-driven algorithm for HPC collection to predict the required volume of donor blood to process in order to meet a CD34+ target. We then prospectively assessed the efficacy of the predictive model in NMDP donors

5 Methods Collection Device: Cobe Spectra & Spectra Optia Anticoagulant: ACD-A/Heparin 11 unit/ml Single day collections are standard Donor blood processed: 24L (Before truncation algorithm) After predicted algorithm initiated Terminate collection when CD34 goal is estimated to be achieved Pre-collection CD34 count is typically available within 2-3 hours of starting collection

6 Methods We evaluated the CD34+ cellular collection efficiency 2 (CE2) in consecutive adult allogeneic (A-allo) collections ( training set ) CE2= CD34 cells collected/(bvp x precollection CD34 count) Mean (1SD) CD34 CE2s (N): A-allo- 51% (14%)- 59 donors

7 Methods Prediction of Blood Volume to be Processed (BVP) was calculated as follows: BVP = CD34 cell target CD34 CE2 x Precollection PB CD34 Count

8 Methods In order to have a high level of confidence that the targeted dose of cells is collected, the CD34 CE2 in the prediction formula was set at: 30% (lowest CE2 attained in allo patients in the training set )

9 Results Performance of the prediction formula was evaluated in HPC collections in NMDP donors over 6 months

10 Truncation vs Pre Truncation Era: Donors age was similar n=12 n=14

11 Truncation vs Pre Truncation Era: Donors similarly mobilized n=12 n=14

12 Results Procedures truncated in the 6 month period: 8 of 14 = 57%

13 BVP: Significantly smaller in truncated procedures

14 Significantly fewer platelets depleted in truncated procedures

15 Better Mobilized patients more likely to be truncated

16 CD34 Yield All truncated collections resulted in adequate collection of CD34 cells (> target dose requested) 1

17 Current Process: Prediction 2.0 Now we use 42% CE2 in our prediction algorithm A minimum of 10L is processed currently, even if the truncation prediction suggests <10L

18 Conclusion A high % of NMDP collections were truncated using our prediction algorithm Lesser platelet depletion in truncated donors As expected, truncation was recommended in donors more likely to be better mobilized

19 Conclusion No prediction failures thus far The volume of BVP truncated was significantly lower (~by 9L on average) compared to non-truncated procedures We are continuing to implement algorithm in all referred NMDP donors

20 Conclusion This approach may be particularly important in mitigating risks of LVL such as volume overload/citrate toxicity and promoting optimal use of healthcare resources and enhances donor convenience and satisfaction

21 Acknowledgments BloodCenter of Wisconsin: - Kenneth Friedman - Sorelle Jefcik - Jean Wucinski - Lori Eggert - Patricia Fredrich - BCW Apheresis RNs Medical College of Wisconsin: - Carolyn Keever-Taylor - David Margolis - Parameswaran Hari - Volunteer PBSC donors

Algorithms to predict CD34+ cell collection with the new generation of cell separator machines

Algorithms to predict CD34+ cell collection with the new generation of cell separator machines Algorithms to predict CD34+ cell collection with the new generation of cell separator machines Dr Kenny Douglas SNBTS Clinical Apheresis Unit Beatson West of Scotland Cancer Centre Glasgow, U.K. Predicting

More information

ISCT Workshop #7 Perspectives in Cell Selection Immunomagnetic Selection

ISCT Workshop #7 Perspectives in Cell Selection Immunomagnetic Selection ISCT Workshop #7 Perspectives in Cell Selection Immunomagnetic Selection Carolyn A. Keever-Taylor, PhD Medical College of Wisconsin June 7, 2012 History of Available Devices CellPro CEPRATE Avidin/Biotin

More information

Edwin A. Burgstaler MT, HP (ASCP) Jeffrey L. Winters MD. ASFA 2017 Annual Meeting May 5, MFMER slide-1

Edwin A. Burgstaler MT, HP (ASCP) Jeffrey L. Winters MD. ASFA 2017 Annual Meeting May 5, MFMER slide-1 Comparison of Hematopoietic Progenitor Cell (HPC) Collection Using the Spectra Optia Continuous Mononuculear Cell (CMNC) Collections with a 26:1 Anticoagulant Ratio Versus an Anticoagulant ing Technique

More information

BMTCN REVIEW COURSE PRE-TRANSPLANT CARE

BMTCN REVIEW COURSE PRE-TRANSPLANT CARE BMTCN REVIEW COURSE PRE-TRANSPLANT CARE Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to edit the Master Experts

More information

WAA/SFH Joint Congress

WAA/SFH Joint Congress WAA/SFH Joint Congress Paris, 27 29 April 2016 Mobilization of HSC: History, evolution & impact Pitié-Sâlpétrière Hospital-Paris- France University Hospital of Paris-VI Nabih AZAR MD Key areas covered

More information

Leukopak 101: A Brief Review of Apheresis

Leukopak 101: A Brief Review of Apheresis White Paper September 2016 Leukopak 101: A Brief Review of Apheresis Lily C. Trajman, Ph.D. Introduction Apheresis refers to the process by which blood is removed from a patient and separated into its

More information

Regulatory Challenges in Apheresis Global Perspectives - Cell Therapy

Regulatory Challenges in Apheresis Global Perspectives - Cell Therapy Regulatory Challenges in Apheresis Global Perspectives - Cell Therapy Joseph (Yossi ) Schwartz, MD, MPH Director, Transfusion Medicine & Cellular Therapy Columbia University Medical Center New York Presbyterian

More information

A PRIMER ON APHERESIS MEDICINE

A PRIMER ON APHERESIS MEDICINE A PRIMER ON APHERESIS MEDICINE Nicole Aqui, M.D. Assistant Professor Division of Transfusion Medicine Department of Pathology and Laboratory Medicine University of Pennsylvania What is Apheresis? Apheresis

More information

34 th Annual Meeting of ASFA, May 22-25, 2013, Denver, CO

34 th Annual Meeting of ASFA, May 22-25, 2013, Denver, CO 34 th Annual Meeting of ASFA, May 22-25, 2013, Denver, CO Conflict of Interest F. Tekin Turhan has received consulting, travel and accommodation support from Terumo BCT Co-authors have nothing to declare

More information

Characteristics of CD34-Enriched Products Processed at Multiple Centers Using the CliniMACS System - BMT CTN 0303

Characteristics of CD34-Enriched Products Processed at Multiple Centers Using the CliniMACS System - BMT CTN 0303 Characteristics of CD34-Enriched Products Processed at Multiple Centers Using the CliniMACS System - BMT CTN 0303 Carolyn Keever-Taylor, Steven M Devine, Robert J Soiffer, Shelly L Carter, Marcelo Pasquini,

More information

FormsNet Adverse Event Form

FormsNet Adverse Event Form FormsNet Adverse Event Form Registry Use Only Sequence Number: Date Received: Recipient Identification 1. CIBMTR Recipient ID (CRID): 2. NMDP Recipient ID (RID): (if applicable) - - 3. CIBMTR Center Number

More information

The New Zealand Experience

The New Zealand Experience Platelet Collections using TRIMA. The New Zealand Experience Dr Anup Chand 20th November 2016 Disclaimer I have no financial interest in TERUMO BCT or any other company Content Introduction Donor PAS

More information

& 2003 Nature Publishing Group All rights reserved /03 $

& 2003 Nature Publishing Group All rights reserved /03 $ (2003) 31, 263 267 & 2003 Nature Publishing Group All rights reserved 0268-3369/03 $25.00 www.nature.com/bmt Progenitor cell mobilization : safety profile and variables affecting peripheral blood progenitor

More information

Therapeutic Apheresis Services Annual Review 2016/17

Therapeutic Apheresis Services Annual Review 2016/17 Therapeutic Apheresis Services Annual Review 2016/17 NHS Blood and Transplant (NHSBT) is a major provider of Therapeutic Apheresis Services (TAS) in the NHS. Services are provided across England. Collection

More information

STEM CELL TRANSPLANT IN PEDIATRICS. Erin Meyer, DO, MPH Medical Director, Apheresis Nationwide Children s Hospital Columbus, OH 5/6/17

STEM CELL TRANSPLANT IN PEDIATRICS. Erin Meyer, DO, MPH Medical Director, Apheresis Nationwide Children s Hospital Columbus, OH 5/6/17 STEM CELL TRANSPLANT IN PEDIATRICS Erin Meyer, DO, MPH Medical Director, Apheresis Nationwide Children s Hospital Columbus, OH 5/6/17 Disclosures Nothing to Disclose Overview Stem Cell Transplant History

More information

APHERESIS PROCEDURES. Worldwide implemented nowadays. Most of Asian Countries also involved. The usage of this procedure varies between countries.

APHERESIS PROCEDURES. Worldwide implemented nowadays. Most of Asian Countries also involved. The usage of this procedure varies between countries. ASIA COUNTRIES AS APHERESIS PROCEDURES Worldwide implemented nowadays. Most of Asian Countries also involved. The usage of this procedure varies between countries. SPECTRUM OF APHERESIS Therapeutic Apheresis

More information

Therapeutic Apheresis in South America

Therapeutic Apheresis in South America Therapeutic Apheresis in South America Alfredo Mendrone Jr, MD, PhD Fundação Pró-Sangue Hemocentro de SP / University of São Paulo São Paulo - Brazil Therapeutic Apheresis in Brazil The beginning... Late

More information

Spanish Donor Registry. Follow-Up Data

Spanish Donor Registry. Follow-Up Data Spanish Donor Registry. Follow-Up Data Javier de la Rubia S. de Hematología Hospital La Fe Valencia 16th Haemovigilance Seminar Barcelona, March 2014 WHO declared 2010 in its Guiding principle Nr.10: Hig-quality,

More information

Review of New Platforms for Blood Prime

Review of New Platforms for Blood Prime Review of New Platforms for Blood Prime Edwin A. Burgstaler, MT, HP(ASCP) ASFA 2015 Annual Meeting May, 2015 2015 MFMER slide-1 Objectives The participant will recognize the basic steps in performing a

More information

KEY WORDS: Hematopoietic stem cell mobilization, Granulocyte colony-stimulating factor, Healthy donor, Apheresis

KEY WORDS: Hematopoietic stem cell mobilization, Granulocyte colony-stimulating factor, Healthy donor, Apheresis Factors Associated with Peripheral Blood Stem Cell Yield in Volunteer Donors Mobilized with Granulocyte Colony-Stimulating Factors: The Impact of Donor Characteristics and Procedural Settings Tso-Fu Wang,

More information

Carlos Bachier, Josh Potter, Grant Potter, Rominna Sugay, Paul Shaughnessy, Kawah Chan, Veronica Jude, Renee Madden, Charles F.

Carlos Bachier, Josh Potter, Grant Potter, Rominna Sugay, Paul Shaughnessy, Kawah Chan, Veronica Jude, Renee Madden, Charles F. High White Blood Cell Concentration in the Peripheral Blood Stem Cell Product Can Induce Seizures during Infusion of Autologous Peripheral Blood Stem Cells Carlos Bachier, Josh Potter, Grant Potter, Rominna

More information

Developing a Quality Dashboard An Evidence Based Approach PURPOSE/OBJECTIVES:

Developing a Quality Dashboard An Evidence Based Approach PURPOSE/OBJECTIVES: Developing a Quality Dashboard An Evidence Based Approach PURPOSE/OBJECTIVES: 1. To discuss the process that NYUHC Oncology Nursing Services used to develop and maintain a quality dashboard. 2. To define

More information

Comparison of Spectra Optia and COBE Spectra apheresis systems performances for Red Blood Cell Exchange procedures

Comparison of Spectra Optia and COBE Spectra apheresis systems performances for Red Blood Cell Exchange procedures Comparison of and COBE apheresis systems performances for Red Blood Cell Exchange procedures Jaehyup Kim MD PhD UT Southwestern Medical Center COBE and COBE (Terumo BCT, Lakewood, Co) has been the mainstay

More information

Back to the Future: The Resurgence of Bone Marrow??

Back to the Future: The Resurgence of Bone Marrow?? Back to the Future: The Resurgence of Bone Marrow?? Thomas Spitzer, MD Director. Bone Marrow Transplant Program Massachusetts General Hospital Professor of Medicine, Harvard Medical School Bone Marrow

More information

Introduction to Hematopoietic Stem Cell Transplantation

Introduction to Hematopoietic Stem Cell Transplantation Faculty Disclosures Introduction to Hematopoietic Stem Cell Transplantation Nothing to disclose Jeanne McCarthy-Kaiser, PharmD, BCOP Clinical Pharmacist, Autologous Stem Cell Transplant/Long- Term Follow-Up

More information

Donor work up, follow up and ethical issues

Donor work up, follow up and ethical issues Donor work up, follow up and ethical issues Hans Hägglund MD. PhD. Associate Professor Hematology Center, Karolinska University Hospital, Stockholm, Sweden Outline The donor has been identified as a match

More information

Bor-Sheng Ko. Hematology Division, Department of Internal Medicine, National Taiwan University Hospital

Bor-Sheng Ko. Hematology Division, Department of Internal Medicine, National Taiwan University Hospital Bor-Sheng Ko Hematology Division, Department of Internal Medicine, National Taiwan University Hospital On behalf of Members of Aplastic Anemia Consensus Meeting Diagnosis and classification: Treatment

More information

NICE Guidance on Spectra Optia for automated red cell exchange in patients with Sickle Cell Disease

NICE Guidance on Spectra Optia for automated red cell exchange in patients with Sickle Cell Disease NICE Guidance on Spectra Optia for automated red cell exchange in patients with Sickle Cell Disease Dr Jo Howard Guy s and St Thomas NHS Foundation Trust Conflicts of interest Co-investigator/Key opinion

More information

Donatore HLA identico di anni o MUD giovane?

Donatore HLA identico di anni o MUD giovane? Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events

More information

Hematopoietic stem cell mobilization and collection. Koen Theunissen Hematologie Jessa Ziekenhuis Hasselt Limburgs Oncologisch Centrum

Hematopoietic stem cell mobilization and collection. Koen Theunissen Hematologie Jessa Ziekenhuis Hasselt Limburgs Oncologisch Centrum Hematopoietic stem cell mobilization and collection Koen Theunissen Hematologie Jessa Ziekenhuis Hasselt Limburgs Oncologisch Centrum Transplants Transplant Activity in the U.S. 1980-2010 14,000 12,000

More information

Disclosure. Presented analysis part of larger study funded by Terumo BCT

Disclosure. Presented analysis part of larger study funded by Terumo BCT 1 Comparison of Transfusion Adverse Events in Children with Sickle Cell Disease (SCD) Receiving or Automated Red Blood Cell Exchange (arbx) Transfusions for Stroke Prevention Shannon Kelly, M.D. 2 Disclosure

More information

. TCR Alpha, Beta and CD19+ Cell Depleted Haploidentical Transplant for Primary Immunodeficiency Disorders Feb 22 nd,2018

. TCR Alpha, Beta and CD19+ Cell Depleted Haploidentical Transplant for Primary Immunodeficiency Disorders Feb 22 nd,2018 . TCR Alpha, Beta and CD19+ Cell Depleted Haploidentical Transplant for Primary Immunodeficiency Disorders Feb 22 nd,2018 Neena Kapoor Professor of Pediatrics Children s Hospital Los Angeles Keck School

More information

Dr.PSRK.Sastry MD, ECMO

Dr.PSRK.Sastry MD, ECMO Peripheral blood stem cell transplantation (Haematopoietic stem cell transplantation) Dr.PSRK.Sastry MD, ECMO Consultant, Medical Oncology Kokilaben Dhirubhai Ambani Hospital Normal hematopoiesis Historical

More information

Neutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt

Neutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt Neutrophil Recovery: The First Step in Posttransplant Recovery No conflicts of interest to disclose Bus11_1.ppt Blood is Made in the Bone Marrow Blood Stem Cell Pre-B White cells B Lymphocyte T Lymphocyte

More information

"Chemotherapy based stem cell mobilization: pro and con"

Chemotherapy based stem cell mobilization: pro and con "Chemotherapy based stem cell mobilization: pro and con" Mohamad MOHTY Clinical Hematology and Cellular Therapy Dpt. Sorbonne Université Hôpital Saint Antoine Paris, France Disclosures Sponsorship or research

More information

Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT

Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT Erin Meyer, DO, MPH Assistant Medical Director of Blood, Tissue, and Apheresis Services Children s Healthcare

More information

Case Study 1: Red Cell Exchange

Case Study 1: Red Cell Exchange Case Study 1: Red Cell Exchange Education Session VI: Pediatric Apheresis Leon Su, MD Section Chief, Transfusion Medicine and Apheresis None Disclosures 8 year old female SCD History of CVA in 2012 Hgb

More information

Graft source and Stem cell collection SULADA PUKIAT, MD

Graft source and Stem cell collection SULADA PUKIAT, MD + Graft source and Stem cell collection SULADA PUKIAT, MD + Hematopoietic stem cells Hematopoietic stem cells are CD34 + /CD45 dim /SSC low /FSClow to intermediate Neutrophils Bone NK cells T cells Basophils

More information

CELLULAR THERAPY QUIZ. Correct answers and rationale

CELLULAR THERAPY QUIZ. Correct answers and rationale CELLULAR THERAPY QUIZ Correct answers and rationale In January 2018, registered cellular therapy (CT) facilities were asked to participate in the quiz to determine the educational needs of the users regarding

More information

INFUSION OF HEMATOPOETIC STEM CELLS

INFUSION OF HEMATOPOETIC STEM CELLS INFUSION OF HEMATOPOETIC STEM CELLS BY KARLA BELL RN, CPHON PRESENTED BY JILLIAN CAREY, BSN, RN-BC, CPHON TYPES OF HEMATOPOIETIC CELLS Peripheral Blood Stem Cells (PBSC) Fresh or cryopreserved Cord Blood

More information

The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness.

The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness. The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness. Robert Liwski, MD, PhD, FRCPC Medical Director HLA Typing Laboratory Department of Pathology Dalhousie

More information

b. Welcome new Co-Chair Bronwen Shaw, MD, PhD; Anthony Nolan Research Institute, London, UK;

b. Welcome new Co-Chair Bronwen Shaw, MD, PhD; Anthony Nolan Research Institute, London, UK; Not for publication or presentation AGENDA CIBMTR WORKING COMMITTEE FOR DONOR HEALTH AND SAFETY Salt Lake City, UT Thursday, February 14, 2013, 2:45 pm - 4:45 pm Co-Chair: David Stroncek, MD, National

More information

Improving the Outcome of Stem Cell Transplants for Cancer Treatment Using Multivirus-Specific T Cells (Viralym-M)

Improving the Outcome of Stem Cell Transplants for Cancer Treatment Using Multivirus-Specific T Cells (Viralym-M) OFF-THE-SHELF T CELL THERAPY FOR CANCER PATIENTS FOLLOWING STEM CELL TRANSPLANT Improving the Outcome of Stem Cell Transplants for Cancer Treatment Using Multivirus-Specific T Cells (Viralym-M) Ann M.

More information

Objectives. What is Aplastic Anemia. SAA 101: An Introductory Course to Severe Aplastic Anemia

Objectives. What is Aplastic Anemia. SAA 101: An Introductory Course to Severe Aplastic Anemia SAA 101: An Introductory Course to Severe Aplastic Anemia David A. Margolis, MD Professor of Pediatrics/Medical College of Wisconsin Program Director/ Children s Hospital of Wisconsin BMT Program Objectives

More information

Hematopoietic Stem Cell Therapy

Hematopoietic Stem Cell Therapy Hematopoietic Stem Cell Therapy Grace Totoe, MBChB, SBB CME August 2012 Accra-Ghana Hematopoietic Stem Cells Cells capable of self renewal and differentiation into all blood cell lineages Objectives Historical

More information

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions

More information

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient 1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical

More information

Blood Group Incompatible Renal Transplantation and Apheresis. Liz Wright Clinical Nurse Specialist Great Ormond Street Hospital NHS FT

Blood Group Incompatible Renal Transplantation and Apheresis. Liz Wright Clinical Nurse Specialist Great Ormond Street Hospital NHS FT Blood Group Incompatible Renal Transplantation and Apheresis Liz Wright Clinical Nurse Specialist Great Ormond Street Hospital NHS FT Background There is growing interest in transplantation across the

More information

How Much Can We Ask of An Apheresis Donor?

How Much Can We Ask of An Apheresis Donor? How Much Can We Ask of An Apheresis Donor? ASFA 2017 Francis S. Morrison Memorial Lectureship Susan F. Leitman, MD Department of Transfusion Medicine National Institutes of Health Bethesda, MD Francis

More information

White Cell Depletion for Leukocytosis

White Cell Depletion for Leukocytosis White Cell Depletion for Leukocytosis Objectives Discuss the indication for leukoreduction Identify IV access needs for patients receiving leukapheresis Outline ways to maintain fluid and electrolyte balance

More information

Disclosures. Relevant Financial Relationship(s): List or Nothing to Disclose. Off Label Usage: List or Nothing to Disclose 12/9/2016

Disclosures. Relevant Financial Relationship(s): List or Nothing to Disclose. Off Label Usage: List or Nothing to Disclose 12/9/2016 Staffing to Workload Joy Gomez December 12, 2016 Disclosures Relevant Financial Relationship(s): List or Nothing to Disclose Off Label Usage: List or Nothing to Disclose 1 Objectives Discuss data driven

More information

Paired Comparison of Therapeutic Plasma Exchange using Fenwal Amicus vs. TerumoBCT Spectra Optia

Paired Comparison of Therapeutic Plasma Exchange using Fenwal Amicus vs. TerumoBCT Spectra Optia Paired Comparison of Therapeutic Plasma Exchange using Fenwal Amicus vs. TerumoBCT Spectra Optia Edwin A. Burgstaler MT, HP (ASCP) Sandra C. Bryant M.S. Jeffrey L. Winters M.D. ASFA Annual Meeting May

More information

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match CLINICAL RESEARCH Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, 1 Mukta Arora, 2 Stephen Spellman, 1 Michelle Setterholm, 1 Mary Horowitz, 3

More information

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant

More information

Pediatric Hematopoietic Stem Cell Transplant - Experience of an Indian Tertiary Care Center

Pediatric Hematopoietic Stem Cell Transplant - Experience of an Indian Tertiary Care Center Pediatric Hematopoietic Stem Cell Transplant - Experience of an Indian Tertiary Care Center Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology

More information

Acknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center

Acknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center The Addition of Extracorporeal Photopheresis (ECP) to Tacrolimus and Methotrexate to Prevent Acute and Chronic Graft- Versus Host Disease in Myeloablative Hematopoietic Cell Transplant (HCT) Anthony Accurso,

More information

Understanding the role of ex vivo T cell depletion

Understanding the role of ex vivo T cell depletion Prevention of graftversus-host disease (GVHD) Understanding the role of ex vivo T cell depletion Information for patients undergoing allogeneic stem cell transplantation in AML and their families 2 This

More information

3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)

3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) 3 Results 3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) Five infusions of monoclonal IL-2 receptor antibody (anti-cd25) were planned according to protocol between day 0 and day

More information

An Overview of Blood and Marrow Transplantation

An Overview of Blood and Marrow Transplantation An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit

More information

Sterility Testing of Peripheral Blood Stem cell (PBSC) harvests in a Tertiary Oncology Setup

Sterility Testing of Peripheral Blood Stem cell (PBSC) harvests in a Tertiary Oncology Setup Sterility Testing of Peripheral Blood Stem cell (PBSC) harvests in a Tertiary Oncology Setup Bankar S 1, Tirlotkar A 1, Ojha S 1, Bhat V 2,Kannan S 3, Rajadhyaksha S 1 1. Department of Transfusion Medicine,

More information

Therapeutic apheresis (introduction) Orieji Illoh, MD November 21, 2006

Therapeutic apheresis (introduction) Orieji Illoh, MD November 21, 2006 Therapeutic apheresis (introduction) Orieji Illoh, MD November 21, 2006 Apheresis Removal of blood Separation into component parts One component is retained and remainder is returned History First tried

More information

MUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK

MUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British

More information

BMT Winter Workshop. Agenda: 2:00-3:00 PM Meet and Greet. Friday, November 30 th, The NAT, San Diego, CA

BMT Winter Workshop. Agenda: 2:00-3:00 PM Meet and Greet. Friday, November 30 th, The NAT, San Diego, CA BMT Winter Workshop Friday, November 30 th, 2018 The NAT, San Diego, CA Workshop Focus: Section 1. Allogeneic Stem Cell Transplantation and GVHD Section 2. Novel Approaches in Stem Cell Transplantation

More information

Summary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016

Summary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016 Page 1 of 8 Date: July 22, 2016 Summary of Changes Page BMT CTN 1205 Protocol #4 Dated July 22, 2016 The following changes, and the rationale for the changes, were made to the attached protocol in this

More information

Telephone: ; Fax: ; E mail:

Telephone: ; Fax: ; E mail: MINUTES AND OVERVIEW PLAN CIBMTR WORKING COMMITTEE FOR GRAFT SOURCES & MANIPULATION Grapevine, TX Thursday, February 27, 2014, 2:45 4:45 pm Co Chair: Co Chair: Co Chair: Statisticians: Scientific Director:

More information

Carol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT

Carol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT Carol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT History Why is blood transfusion involved? What tests are performed in blood transfusion and why? What does a protocol look

More information

Global Perspective on Donor and Recipient Safety: Biovigilance in Hematopoietic Cell Transplantation

Global Perspective on Donor and Recipient Safety: Biovigilance in Hematopoietic Cell Transplantation Global Perspective on Donor and Recipient Safety: Biovigilance in Hematopoietic Cell Transplantation John P. Miller, MDPhD Vice President and Senior Medical Director National Marrow Donor Program / Be

More information

CORPORATE PROGRAM AND EXHIBITOR GUIDE CORPORATE PROGRAM AND EXHIBITOR GUIDE

CORPORATE PROGRAM AND EXHIBITOR GUIDE CORPORATE PROGRAM AND EXHIBITOR GUIDE CORPORATE PROGRAM CORPORATE PROGRAM AND EXHIBITOR GUIDE Visit www.apheresis.org The corporate satellite symposiums are separate from the ASFA official CME Program and do not confer any CME Credit. 301-750

More information

L Karlsson 1, D Quinlan 1, D Guo 1, C Brown 1,2, S Selinger 2, J Klassen 2 and JA Russell 1,2. Summary:

L Karlsson 1, D Quinlan 1, D Guo 1, C Brown 1,2, S Selinger 2, J Klassen 2 and JA Russell 1,2. Summary: (04) 33, 709 713 & 04 Nature Publishing Group All rights reserved 0268-3369/04 $25.00 www.nature.com/bmt Peripheral blood stem cells : experience compared in 171 donors with particular reference to pain

More information

What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016

What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates

More information

ORIGINAL ARTICLE Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device a local experience

ORIGINAL ARTICLE Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device a local experience Malaysian J Pathol 2008; 30(1) : 31 36 ORIGINAL ARTICLE Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device a local experience CF Leong FRCPA, Habsah

More information

CIBMTR Center Number: CIBMTR Recipient ID: Today s Date: Date of HSCT for which this form is being completed:

CIBMTR Center Number: CIBMTR Recipient ID: Today s Date: Date of HSCT for which this form is being completed: Chronic Myelogenous Leukemia (CML) Post-HSCT Data Sequence Number: Date Received: Registry Use Only Today s Date: Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic,

More information

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000

More information

Transplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust

Transplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust Transplantation - Challenges for the future Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust Bone Marrow Transplantation Timeline, 1957-2006 Appelbaum F. N Engl J Med 2007;357:1472-1475

More information

Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT

Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Stephen Spellman, MBS Director, Immunobiology and Observational Research Assistant Scientific Director CIBMTR,

More information

Therapeutic Leukocyte Reduction (TLR) For Myeloid Leukaemia's : A Four Year Experience From An Oncology Centre In India

Therapeutic Leukocyte Reduction (TLR) For Myeloid Leukaemia's : A Four Year Experience From An Oncology Centre In India Therapeutic Leukocyte Reduction (TLR) For Myeloid Leukaemia's : A Four Year Experience From An Oncology Centre In India Anita Tendulkar, Jain P, Gupta A, Sharma N, Navkudkar A, Patle V Dr Anita Tendulkar

More information

Hematopoietic Stem Cells

Hematopoietic Stem Cells Hematopoietic Stem Cells, Stem Cell Processing, and Joseph (Yossi) Schwartz, M irector, Hemotherapy and Stem Cell Processing Facility E-mail: js2745@columbia.edu Hematopoietic Stem Cells Sustain hematopoiesis

More information

Stem Cell Collection & Cryo Preservation

Stem Cell Collection & Cryo Preservation Stem Cell Collection & Cryo Preservation Dr. B. K. Madhan Kumar Consultant Transfusion Medicine SIMS Hospitals Chennai Stem Cell Definition Blank cells (unspecialized) Capable of dividing and renewing

More information

Allogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra

Allogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) Berlin, Germany September 8-11, 2011 Vienna Austria Allogeneic SCT for CML Allogeneic after failure

More information

General Terms: Appendix B. National Marrow Donor Program and The Medical College of Wisconsin

General Terms: Appendix B. National Marrow Donor Program and The Medical College of Wisconsin Glossary of Terms This appendix is divided into two sections. The first section, General Terms, defines terms used throughout the CIBMTR data collection forms. The second section, FormsNet TM 2 Terms,

More information

21/05/2018. Continuing Education. Presentation Recording. learn.immucor.com

21/05/2018. Continuing Education. Presentation Recording. learn.immucor.com Transplant Webinar Series: Ep. 6 Donor Selection for Haematopoietic Stem Cell Transplantation Future Webinars The Role of NGS in the Transplant Setting Featuring Dr Sujatha Krishnakumar Sirona Genomics,

More information

Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD

Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state

More information

SKIN CANCER AFTER HSCT

SKIN CANCER AFTER HSCT SKIN CANCER AFTER HSCT David Rice, PhD, MSN, RN, NP, NEA-BC Director, Education, Evidence-based Practice and Research City of Hope National Medical Center HOW THE EXPERTS TREAT HEMATOLOGIC MALIGNANCIES

More information

Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split dose escalating study

Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split dose escalating study (2) 25, 371 376 2 Macmillan Publishers Ltd All rights reserved 268 3369/ $15. www.nature.com/bmt Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split

More information

Allogeneic donor selection and blood collection. by Mohammed Abu-basha

Allogeneic donor selection and blood collection. by Mohammed Abu-basha Allogeneic donor selection and blood collection 1 An allogeneic (also called homologous) donation (allo- from the Greek meaning "other") is when a donor gives blood for storage at a blood bank for transfusion

More information

Hematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte-macrophage colonystimulating factor (G-CSF).

Hematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte-macrophage colonystimulating factor (G-CSF). Hematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte colony-stimulating factor(g-csf). Granulocyte-macrophage colonystimulating factor (G-CSF). Interleukin-11

More information

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital

More information

Hematopoiesis i starts from. HPC differentiates t to sequentially more mature. HPC circulate in very low

Hematopoiesis i starts from. HPC differentiates t to sequentially more mature. HPC circulate in very low Upstate Cord Blood Bank Hematopoietic Progenitor Cells Hematopoiesis i starts from self renewing HPC HPC differentiates t to sequentially more mature blood cells HPC circulate in very low numbers in adults

More information

Primary prophylaxis of invasive fungal infection in patients with haematological diseases

Primary prophylaxis of invasive fungal infection in patients with haematological diseases Primary prophylaxis of invasive fungal infection in patients with haematological diseases Tunis, May 24 2012 Important questions for antifungal prophylaxis Who are the patients at risk? Which is the risk:

More information

Autologous hematopoietic stem cell (HSC)

Autologous hematopoietic stem cell (HSC) TRANSPLANTATION AND CELLULAR ENGINEERING Adverse events of cryopreserved hematopoietic stem cell infusions in adults: a single-center observational study Zaher K. Otrock, Diane S. Sempek, Sherry Carey,

More information

Disclosures. Investigator-initiated study funded by Astellas

Disclosures. Investigator-initiated study funded by Astellas Disclosures Investigator-initiated study funded by Astellas 1 Background Widespread use of preemptive therapy strategies has decreased CMV end-organ disease to 5-8% after HCT. Implications for development

More information

An Approach to the Patient Refractory to Platelets Transfusion. Harold Alvarez, MD

An Approach to the Patient Refractory to Platelets Transfusion. Harold Alvarez, MD Harold Alvarez, MD Objectives Explain the etiology of platelet refractoriness Discuss the different types of platelet refractoriness Describe how platelet refractoriness is diagnosed Discuss different

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Gragert L, Eapen M, Williams E, et al. HLA match likelihoods

More information

Unrelated Donor StemCell Transplantation: The Role of the National Marrow Donor Program

Unrelated Donor StemCell Transplantation: The Role of the National Marrow Donor Program Unrelated Donor StemCell Transplantation: The Role of the National Marrow Donor Program August 01, 2003 Palliative and Supportive Care [1], Oncology Journal [2] By Chatchada Karanes, MD [3], Dennis Confer,

More information

An Introduction to Bone Marrow Transplant

An Introduction to Bone Marrow Transplant Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,

More information

Biol Blood Marrow Transplant 19 (2013) 255e259

Biol Blood Marrow Transplant 19 (2013) 255e259 Biol Blood Marrow Transplant 19 (2013) 255e259 Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic

More information

COHEM Barcellona 2012 Hemoglobinopathies debate

COHEM Barcellona 2012 Hemoglobinopathies debate COHEM Barcellona 2012 Hemoglobinopathies debate September 8, 2012: h. 10:30-12:00 Hall: A Is it justified to perform BMT in hemoglobinopathies using unrelated and/or partially mismatched donors? HSCT indication

More information

Factors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection

Factors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection Factors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection Alison Logan Transplantation Laboratory Manchester Royal Infirmary Haematopoietic progenitor cell transplants

More information

ASBMT. Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization

ASBMT. Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization Biol Blood Marrow Transplant 19 (2013) 87e93 Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization ASBMT American Society for

More information

LONG TERM FOLLOW-UP OF PATIENTS WITH FANCONI ANEMIA AFTER ALLOGENEIC T-CELL DEPLETED HEMATOPOITEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS

LONG TERM FOLLOW-UP OF PATIENTS WITH FANCONI ANEMIA AFTER ALLOGENEIC T-CELL DEPLETED HEMATOPOITEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS LONG TERM FOLLOW-UP OF PATIENTS WITH FANCONI ANEMIA AFTER ALLOGENEIC T-CELL DEPLETED HEMATOPOITEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS Farid Boulad, Susan E Prockop, Praveen Anur, Danielle

More information